Cargando…

Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65

Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, JiaLi, Feng, YaDong, Song, GuoXin, Gong, QiXing, Yin, Li, Hu, YingYing, Luo, Dan, Yin, ZhiQiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827091/
https://www.ncbi.nlm.nih.gov/pubmed/29520229
http://dx.doi.org/10.3389/fphar.2018.00067
_version_ 1783302426698186752
author Xu, JiaLi
Feng, YaDong
Song, GuoXin
Gong, QiXing
Yin, Li
Hu, YingYing
Luo, Dan
Yin, ZhiQiang
author_facet Xu, JiaLi
Feng, YaDong
Song, GuoXin
Gong, QiXing
Yin, Li
Hu, YingYing
Luo, Dan
Yin, ZhiQiang
author_sort Xu, JiaLi
collection PubMed
description Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control, Tacrolimus (0.03%), UVB (180 mJ/cm(2)), and UVB (180 mJ/cm(2)) + Tacrolimus (0.03%). Four time points were set as follows: 0, 18, 24, and 48 h. We collected culture medium and tissues at each time point. The percentage of CD1a+ cells in the medium was detected by means of flow cytometry. Each tissue was prepared for immunohistochemistry, real-time quantitative PCR, and western blot. HaCaT cells were cultured and divided into four groups: Control, Tacrolimus (1 μg/ml), UVB (30 mJ/cm(2)), and UVB (30 mJ/cm(2)) + Tacrolimus (1 μg/ml). The cells were incubated for 24 h and prepared for real-time quantitative PCR and western blot. Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium. Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-α expression in cultured tissues. Finally, TNF-α antagonist (recombinant human TNF-α receptor II: IgG Fc fusion protein) could significantly reverse UVB irradiation-induced epidermal LC reduction. Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-α secretion in keratinocytes via regulation of NF-κB/p65.
format Online
Article
Text
id pubmed-5827091
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58270912018-03-08 Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 Xu, JiaLi Feng, YaDong Song, GuoXin Gong, QiXing Yin, Li Hu, YingYing Luo, Dan Yin, ZhiQiang Front Pharmacol Pharmacology Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control, Tacrolimus (0.03%), UVB (180 mJ/cm(2)), and UVB (180 mJ/cm(2)) + Tacrolimus (0.03%). Four time points were set as follows: 0, 18, 24, and 48 h. We collected culture medium and tissues at each time point. The percentage of CD1a+ cells in the medium was detected by means of flow cytometry. Each tissue was prepared for immunohistochemistry, real-time quantitative PCR, and western blot. HaCaT cells were cultured and divided into four groups: Control, Tacrolimus (1 μg/ml), UVB (30 mJ/cm(2)), and UVB (30 mJ/cm(2)) + Tacrolimus (1 μg/ml). The cells were incubated for 24 h and prepared for real-time quantitative PCR and western blot. Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium. Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-α expression in cultured tissues. Finally, TNF-α antagonist (recombinant human TNF-α receptor II: IgG Fc fusion protein) could significantly reverse UVB irradiation-induced epidermal LC reduction. Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-α secretion in keratinocytes via regulation of NF-κB/p65. Frontiers Media S.A. 2018-02-22 /pmc/articles/PMC5827091/ /pubmed/29520229 http://dx.doi.org/10.3389/fphar.2018.00067 Text en Copyright © 2018 Xu, Feng, Song, Gong, Yin, Hu, Luo and Yin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xu, JiaLi
Feng, YaDong
Song, GuoXin
Gong, QiXing
Yin, Li
Hu, YingYing
Luo, Dan
Yin, ZhiQiang
Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title_full Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title_fullStr Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title_full_unstemmed Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title_short Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
title_sort tacrolimus reverses uvb irradiation-induced epidermal langerhans cell reduction by inhibiting tnf-α secretion in keratinocytes via regulation of nf-κb/p65
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827091/
https://www.ncbi.nlm.nih.gov/pubmed/29520229
http://dx.doi.org/10.3389/fphar.2018.00067
work_keys_str_mv AT xujiali tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT fengyadong tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT songguoxin tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT gongqixing tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT yinli tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT huyingying tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT luodan tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65
AT yinzhiqiang tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65